Improving drug penetration to curb tumor drug resistance

Fabrizio Marcucci, Angelo Corti

Research output: Contribution to journalArticlepeer-review


Several classes of drugs that we refer to here as 'promoter drugs' can improve tumor uptake and penetration of other drugs that we refer to as 'effector drugs', which exert direct antitumor effects. In this review we discuss the main therapeutic advantages that can be obtained by using promoter drugs. First, tumor-specific enhancement of effector drug accumulation but unaltered accumulation in normal tissues with improvement of the therapeutic index. Second, we propose that curbing tumor drug resistance is another important consequence of using promoter drugs. In particular, we discuss evidence suggesting that promoter drugs can (i) prevent induction of new resistance by paracrine factors released in response to effector drugs, and (ii) reverse existing drug resistance induced by mechanical cues and tumor-cell-extracellular-matrix interactions.

Original languageEnglish
Pages (from-to)1139-1146
Number of pages8
JournalDrug Discovery Today
Issue number19-20
Publication statusPublished - Oct 2012

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Improving drug penetration to curb tumor drug resistance'. Together they form a unique fingerprint.

Cite this